** Figure S1.** **Apigenin inhibits LCA-induced hepatocyte damage.** Huh7 cells were treated with LCA (30 mM) or plus apigenin at the indicated concentrations for 24 h, followed by determination of cell viability by MTT assay. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; API: apigenin.

****

**Figure S2.** **Apigenin reduces the DDC-induced g-GT levels in mouse liver.** Liver sections were conducted immunohistochemical staining to determine g-GT protein expression.

****

**Figure S3. Apigenin inhibits the expression of fibrosis-related factors in the gallbladder wall.** mRNA expression of a-SMA and COL1A1 was determined by qRT-PCR. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; API: apigenin.



**Figure S4. Apigenin has little effects on TBA levels in mouse feces and intestines.** 250 mg feces (dried overnight) and whole intestines were used to extract TBA. Feces (left panel) and intestines (right panel) TBA levels were determined with assay kit. \*\*\*, p < 0.001; API: apigenin.

**­­**

**Figure S5.** **Apigenin activates FXR and SHP in hepatocytes.** Huh7 cells were treated with apigenin (5 mM or 10 mM) for 24h. mRNA or Protein expression of FXR and SHP was determined by qRT-PCR (A) or Western blot with quantitative analysis of band density (B). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; API: apigenin.